AbbVie Inc
ABBV - NEW YORK STOCK EXCHANGE, INC.
Industry: Biotechnology
Market Cap: 329.9 B
IPO Date: Jan 2, 2013
Country: US
Currency: USD
Shares Outstanding: 1.8 B
AbbVie Catches A Break In Termination Fee Tax Court Case
6/27/2025
On June 17, the U.S. Tax Court ruled that AbbVie, Inc. could deduct the fee it paid to terminate its 2014 combination agreement with Shire plc. This decision represents a significant win for AbbVie,...
Source: Finnhub
Touchstone Sands Capital Select Growth Fund Q1 2025 Commentary
6/26/2025
The Touchstone Sands Capital Select Growth Fund (Class A) outperformed its benchmark Index for Q1 ended March 31, 2025. Click here to read the full commentary.
Source: SeekingAlpha
Incyte's New CEO Is A Dealmaking Machine. Will He Bring That Fervor To His New Role?
6/26/2025
Incyte stock popped Thursday after the company's board appointed Bill Meury as its new CEO, replacing Herve Hoppenot, who is retiring.
Source: Yahoo
Here's Why AbbVie (ABBV) is a Strong Momentum Stock
6/26/2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Source: Yahoo
Rosalind Franklin University Helix 51 Company UP Oncolytics Secures Wisconsin Economic Development Matching Grant to Advance Oncolytic Virus Therapy for Brain Cancer
6/25/2025
UP Oncolytics, a neuro-oncology biotechnology company based in Milwaukee and a spin-out of the Advocate Aurora Research Institute, has received a $75,000 matching grant from the Wisconsin Economic Development Corporation (WEDC) in partnership with the University of Wisconsin. The grant supplements the company's $500,000 SBIR Phase I Fast Track award from the National Institutes of Health (NIH), received last year.
Source: Yahoo
Elahere Market Opportunities and Strategies to 2034: Abbvie Secures European Approval for Elahere in Platinum-Resistant Ovarian Cancer
6/25/2025
The global elahere market is set for rapid growth, projected to surge to $6.07 billion by 2034 at a CAGR of 28.68%. Key growth drivers include rising ovarian cancer prevalence, healthcare access in emerging markets, and increased demand for personalized medicine. Despite challenges like high costs and competition, the market, led by AbbVie Inc. (ImmunoGen), presents vast opportunities, particularly in online pharmacies and hospital segments. The fastest growth will occur in Western and Eastern E
Source: Yahoo
My Dividend Stock Portfolio: New May Dividend Record - 100 Holdings With 15 Buys
6/25/2025
Explore May 2025 market volatility, U.S.-China trade talks, and record dividend income growth.
Source: SeekingAlpha
AbbVie (ABBV) Reports Positive Migraine Drug Results in Phase 3 Trial
6/24/2025
AbbVie Inc. (NYSE:ABBV) is one of the 10 undervalued blue chip stocks analysts recommend for smart investing. On June 18, the company published its Phase 3 TEMPLE study results, which were positive. The study evaluated the tolerability, safety, and efficacy of atogepant (marketed as QULIPTA or AQUIPTA) compared to topiramate for the preventive treatment of […]
Source: Yahoo
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
6/24/2025
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
Source: Yahoo
Will AbbVie's Growing Oncology Portfolio Aid Top-line Growth?
6/24/2025
ABBV's growing oncology portfolio, now spanning five therapies, is helping offset Imbruvica's sales decline and boost top-line growth.
Source: Yahoo
Age-Related Vision Dysfunction Market Research 2025-2035 | Kodiak Sciences, Genentech, and AbbVie Drive Innovations Through Advanced, Sustainable Solutions
6/24/2025
The global age-related vision dysfunction (ARVD) market is witnessing robust growth due to the aging population and heightened awareness of eye health. Age-related vision dysfunction encompasses impairments like macular degeneration, cataracts, and glaucoma, affecting quality of life. The market is thriving with innovative solutions, including pharmaceuticals, surgeries, and digital health technologies such as AI diagnostics and telemedicine. Despite economic and regulatory hurdles, advancements
Source: Yahoo
2 Dividend Aristocrats Bargains To Buy And 'Never Let Go'
6/24/2025
Buying Dividend Aristocrats at bargain prices can be a winning investment strategy. Read about two such stocks that are undervalued vs. historical norms.
Source: SeekingAlpha
J&J's Drugs Get CHMP Recommendations for Blood Cancer Indications
6/23/2025
JNJ wins CHMP backing for Darzalex and Imbruvica in new blood cancer uses, paving the way for first-in-class approvals.
Source: Yahoo
Genmab: This Is Anything But A Value Trap, Yet It Is Currently Priced As One
6/23/2025
Discover why Genmab A/S stands out as a high-margin biotech with strong partnerships, robust growth prospects, and undervalued metrics. Click for more on GMAB.
Source: SeekingAlpha
Is AbbVie the Best Dividend Stock in Big Pharma Today?
6/21/2025
AbbVie Inc. (NYSE:ABBV) is one of the best dividend stocks for a bear market. The company holds the title of a Dividend King, having raised its dividend for 52 straight years. That kind of track record makes a dividend cut highly unlikely, as it would break the streak and potentially take decades to regain entry […]
Source: Yahoo
LLY vs. ABBV: Which Pharma Powerhouse is the Better Bet?
6/20/2025
LLY's blockbuster obesity drugs fuel rapid growth but ABBV's valuation and pipeline may offer safer short-term upside.
Source: Yahoo
AbbVie Declares Quarterly Dividend
6/20/2025
The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.64 per share.
Source: Yahoo
AbbVie Inc Declares Quarterly Cash Dividend, Payable August 15, 2025
6/20/2025
The board of directors of AbbVie Inc. declared a quarterly cash dividend of $1.64 per share. The cash dividend is payable August 15, 2025, to stockholders of record at the close of business on July...
Source: Finnhub